Ptc Therapeutics (PTCT) Change in Accured Expenses (2012 - 2026)

Ptc Therapeutics' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at $37.5 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 204.68% year-over-year to $37.5 million; the TTM figure through Jun 2026 stood at $57.8 million (up 281.11% YoY), while the FY2025 annual figure was $71.7 million, up 315.3% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at $37.5 million, up from -$68.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $108.1 million in Q4 2025, with the low at -$68.7 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $8.0 million (2023), against an average of $4.6 million.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses slumped 2171.02% in 2024, then surged 478.05% in 2025.
• Ptc Therapeutics' Change in Accured Expenses stood at $26.0 million in 2022, then slumped by 69.54% to $7.9 million in 2023, then plunged by 461.34% to -$28.6 million in 2024, then soared by 478.05% to $108.1 million in 2025, then slumped by 65.3% to $37.5 million in 2026.
• Business Quant data shows PTCT's Change in Accured Expenses at $37.5 million in Q2 2026, -$68.7 million in Q1 2026, and $108.1 million in Q4 2025.